- Home
- CANF vs OST Comparison
CANF vs OST Comparison
Compare CANF & OST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- OST
- Stock Information
- Founded
- CANF 1994
- OST 2010
- Country
- CANF Israel
- OST China
- Employees
- CANF N/A
- OST N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- OST Industrial Machinery/Components
- Sector
- CANF Health Care
- OST Technology
- Exchange
- CANF Nasdaq
- OST Nasdaq
- Market Cap
- CANF 13.5M
- OST 15.7M
- IPO Year
- CANF N/A
- OST 2022
- Fundamental
- Price
- CANF $0.66
- OST $0.08
- Analyst Decision
- CANF Strong Buy
- OST
- Analyst Count
- CANF 2
- OST 0
- Target Price
- CANF $14.00
- OST N/A
- AVG Volume (30 Days)
- CANF 314.0K
- OST 13.1M
- Earning Date
- CANF 08-29-2025
- OST 08-25-2025
- Dividend Yield
- CANF N/A
- OST N/A
- EPS Growth
- CANF N/A
- OST N/A
- EPS
- CANF N/A
- OST N/A
- Revenue
- CANF $674,000.00
- OST $38,333,251.00
- Revenue This Year
- CANF $461.72
- OST N/A
- Revenue Next Year
- CANF N/A
- OST N/A
- P/E Ratio
- CANF N/A
- OST N/A
- Revenue Growth
- CANF N/A
- OST 0.34
- 52 Week Low
- CANF $0.63
- OST $0.07
- 52 Week High
- CANF $3.24
- OST $9.40
- Technical
- Relative Strength Index (RSI)
- CANF 12.02
- OST 24.90
- Support Level
- CANF $1.00
- OST $0.08
- Resistance Level
- CANF $1.05
- OST $0.09
- Average True Range (ATR)
- CANF 0.05
- OST 0.01
- MACD
- CANF -0.04
- OST 0.19
- Stochastic Oscillator
- CANF 5.86
- OST 9.77
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About OST Ostin Technology Group Co. Ltd.
Ostin Technology Group Co Ltd is a supplier of display modules and polarizers in China. It designs, develops, and manufactures TFT-LCD modules in a wide range of sizes and customized sizes according to the specifications of its customers. Its display modules are mainly used in consumer electronics, commercial LCD displays, and automotive displays. The company also manufactures polarizers used in the TFT-LCD display modules and is in the process of developing polarizers for the OLED display panel. Geographically, the company generates revenue from Hong Kong, Taiwan, and Mainland China which is its key revenue generating market.